ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo
Henry Danahay
1
,
Clive McCarthy
2
,
Thomas Schofield
3
,
Tim Schofield
3
,
Roy Fox
4
,
Holly Charlton
4
,
Sarah Lilley
4
,
Juan Sabater
5
,
MATTHIAS SALATHÉ
6
,
Nathalie Baumlin
6
,
Stephen P Collingwood
2
,
Martin Gosling
2
1
Enterprise Therapeutics Ltd, 60 Science Park Square, Brighton BN1 9SB, UK. Electronic address: henry@enterprisetherapeutics.com.
2
Enterprise Therapeutics Ltd, 60 Science Park Square, Brighton BN1 9SB, UK.
|
3
Evotec UK Ltd, 114 Park Dr, Innovation Dr, Milton, Abingdon, OX14 4RZ, UK.
|
4
Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton, BN1 9RH, UK.
|
5
Department of Research, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL 33140, USA.
|
Publication type: Journal Article
Publication date: 2025-01-01
scimago Q1
wos Q1
SJR: 1.772
CiteScore: 10.0
Impact factor: 6.0
ISSN: 15691993, 18735010
PubMed ID:
38851923
Abstract
Inhibiting ENaC in the airways of people with cystic fibrosis (pwCF) is hypothesized to enhance mucociliary clearance (MCC) and provide clinical benefit. Historically, inhaled ENaC blockers have failed to show benefit in pwCF challenging this hypothesis. It is however unknown whether the clinical doses were sufficient to provide the required long duration of action in the lungs and questions whether a novel candidate could offer advantages where others have failed?
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
|
|
|
Nature Reviews Disease Primers
1 publication, 20%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 20%
|
|
|
Pflugers Archiv European Journal of Physiology
1 publication, 20%
|
|
|
Progress in Medicinal Chemistry
1 publication, 20%
|
|
|
Journal of Cystic Fibrosis
1 publication, 20%
|
|
|
1
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 60%
|
|
|
Springer Nature
2 publications, 40%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
5
Total citations:
5
Citations from 2024:
4
(80%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Danahay H. et al. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo // Journal of Cystic Fibrosis. 2025. Vol. 24. No. 1. pp. 72-78.
GOST all authors (up to 50)
Copy
Danahay H., McCarthy C., Schofield T., Schofield T., Fox R., Charlton H., Lilley S., Sabater J., SALATHÉ M., Baumlin N., Collingwood S. P., Gosling M. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo // Journal of Cystic Fibrosis. 2025. Vol. 24. No. 1. pp. 72-78.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.jcf.2024.06.002
UR - https://linkinghub.elsevier.com/retrieve/pii/S156919932400081X
TI - ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo
T2 - Journal of Cystic Fibrosis
AU - Danahay, Henry
AU - McCarthy, Clive
AU - Schofield, Thomas
AU - Schofield, Tim
AU - Fox, Roy
AU - Charlton, Holly
AU - Lilley, Sarah
AU - Sabater, Juan
AU - SALATHÉ, MATTHIAS
AU - Baumlin, Nathalie
AU - Collingwood, Stephen P
AU - Gosling, Martin
PY - 2025
DA - 2025/01/01
PB - Elsevier
SP - 72-78
IS - 1
VL - 24
PMID - 38851923
SN - 1569-1993
SN - 1873-5010
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2025_Danahay,
author = {Henry Danahay and Clive McCarthy and Thomas Schofield and Tim Schofield and Roy Fox and Holly Charlton and Sarah Lilley and Juan Sabater and MATTHIAS SALATHÉ and Nathalie Baumlin and Stephen P Collingwood and Martin Gosling},
title = {ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
publisher = {Elsevier},
month = {jan},
url = {https://linkinghub.elsevier.com/retrieve/pii/S156919932400081X},
number = {1},
pages = {72--78},
doi = {10.1016/j.jcf.2024.06.002}
}
Cite this
MLA
Copy
Danahay, Henry, et al. “ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.” Journal of Cystic Fibrosis, vol. 24, no. 1, Jan. 2025, pp. 72-78. https://linkinghub.elsevier.com/retrieve/pii/S156919932400081X.